Bivalirudin
- Generic Name
- Bivalirudin
- Brand Names
- Angiomax
- Drug Type
- Small Molecule
- Chemical Formula
- C98H138N24O33
- CAS Number
- 128270-60-0
- Unique Ingredient Identifier
- TN9BEX005G
- Background
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activat...
- Indication
For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.
- Associated Conditions
- Thrombosis
- Associated Therapies
- -
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2017-12-04
- Lead Sponsor
- Cardiovascular Research Foundation, New York
- Target Recruit Count
- 3602
- Registration Number
- NCT00433966
- Locations
- 🇺🇸
LeBauer CV Research Foundation, Greensboro, North Carolina, United States
Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Target Recruit Count
- 1721
- Registration Number
- NCT00373451
- Locations
- 🇩🇪
Medizinische Klinik, Klinikum rechts der Isar, Muenchen, Germany
🇩🇪Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
🇩🇪Herz- und Gefaessklinik, Kardiologie, Bad Neustadt, Germany
ImproveR International (BI-001-IM)
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Nycomed
- Target Recruit Count
- 4000
- Registration Number
- NCT00290849
- Locations
- 🇩🇰
Nycomed, Roskilde, Denmark
Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)
- Conditions
- Interventions
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2010-03-15
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Target Recruit Count
- 4570
- Registration Number
- NCT00262054
- Locations
- 🇩🇪
First Medizinische Klinik, Klinikum rechts der Isar, Munich, Germany
🇩🇪Herz-Zentrum, Bad Krozingen, Germany
🇩🇪Segeberger Kliniken, Bad Segeberg, Germany
Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)
- Conditions
- Interventions
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 150
- Registration Number
- NCT00079586
- Locations
- 🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB
- Conditions
- Interventions
- First Posted Date
- 2003-11-27
- Last Posted Date
- 2011-11-10
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 150
- Registration Number
- NCT00073593
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
- Conditions
- First Posted Date
- 2002-08-16
- Last Posted Date
- 2011-09-16
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 50
- Registration Number
- NCT00043940
- Locations
- 🇺🇸
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.